Thermo Fisher Scientific Inc

NYSE: TMO
$565.23
-$9.34 (-1.6%)
Closing price April 12, 2024
Thermo Fisher Scientific Inc. is a global leader in serving science, with a broad range of high-tech instruments, reagents, and services for research, analysis, discovery, and diagnostics. It caters to various markets including pharmaceuticals, biotechnology, academia, and healthcare, offering products under well-known brands like Thermo Scientific, Applied Biosystems, and Fisher Scientific. From life sciences solutions that aid in drug and vaccine development to analytical instruments for research, and specialty diagnostics for disease diagnosis, Thermo Fisher is integral to scientific advancement and healthcare improvement. Founded in 1956, it operates worldwide, emphasizing innovation and quality.
For health care investors, 2020 looks like a potentially good year after an especially fruitful JPMorgan Healthcare Conference this past week.
The top analyst upgrades, downgrades and initiations seen on Tuesday included AFL, Agilent, Allergan, Barrick Gold, Cognex, Hilton, Lloyds, MetLife, Slack and Wingstop.
Health care stocks still have plenty of upside in them. Agilent, Danaher, Thermo Fisher are all stocks to buy.
The Merrill Lynch team noted that these four stocks had bullish technicals that were most aligned with bullish fundamentals.
Here are five top health care stocks that provide investors with different avenues to invest in the sector. They all should be solid additions to growth portfolios for 2019.
The top analyst upgrades, downgrades and initiations seen on Thursday included AT&T, Boeing, Hilton, KB Home, Microsoft, Norfolk Southern, Pandora and UPS.
Here are the 15 companies that appear most likely to enter or get back into the $100 billion market capitalization club among U.S. stocks.
Managers of the UBS Q-GARP portfolio continue searching for high-quality U.S. growth companies that are trading at attractive valuations. They maintain that recent volatility in the market has had no...
According to a recent analyst report by Janney, the National Institute of Health budget that was approved last Friday could be a big boost for some select biopharma stocks.
According to Merrill Lynch, the health care sector should act as a good hedge against volatility. Even biotech was shown to offer growth at a reasonable price.
The include BioCryst Pharmaceuticals, Exxon Mobil, Fiat Chrysler Automobiles, Hewlett Packard Enterprise, IAMGOLD, Mallinckrodt and Rockwell Collins.
The top analyst upgrades, downgrades and other research calls from Tuesday include Alibaba, Best Buy, Deere, Jinko Solar, Motorola Solutions, Mylan, Redfin and VMware.
The top analyst upgrades, downgrades and other research calls from Friday include Autodesk, IBM, Lumber Liquidators, NVIDIA, Salesforce.com, Symantec, T-Mobile and Wal-Mart.
Pantheon shares saw a huge gain on Monday following the announcement that the company will be acquired by Thermo Fisher Scientific.
Thermo Fisher Scientific said Friday morning that it has agreed to acquire FEI for approximately $4.2 billion in cash.